US Bancorp’s Vor Biopharma VOR Stock Holding History

US Bancorp’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-81	Closed	-$19K	–	4210
2021 Q4	$19K	Buy	81 +75	+1,250%	+$21.6K	﹤0.01%	3147
2021 Q3	$2K	Buy	+6	New	+$1.78K	﹤0.01%	3929

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

US Bancorp's VOR Position: Q1 2022 in Review

US Bancorp sold out of Vor Biopharma (VOR) in Q1 2022, closing a stake of 81 shares — an estimated $19K sold.

US Bancorp first reported a position in VOR in Q3 2021 and held it in 2 quarters. The position peaked at $19K in Q4 2021. 58 funds tracked by Wall St. Rank hold VOR as of Q1 2022.

US Bancorp reported no remaining Vor Biopharma position as of Q1 2022 after selling out during the quarter.
US Bancorp sold 81 Vor Biopharma shares in Q1 2022, an estimated $19K.
US Bancorp first reported a position in Vor Biopharma in Q3 2021 and held it in 2 quarters.
US Bancorp's Vor Biopharma position peaked at $19K in Q4 2021.
58 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2022.

Based on US Bancorp's 13F filing for Q1 2022, filed 11 May 2022.